Evidence map›Paper›PMID 40634092›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Successful Remission of Nephrotic Syndrome Caused by IgA Nephropathy with Membranoproliferative Glomerulonephritis-pattern Lesion Treated by Cyclosporine and Oral Corticosteroids.

Yuki Nakao, Yutaro Mori, Junko Kunieda, Towako Taguchi, Katsuo Mori, Ayumi Yamamura, Shotaro Naito, Fumiaki Ando, Shintaro Mandai, Soichiro Iimori and 5 more

Abstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuki NakaoDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Yutaro MoriDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Junko KuniedaDepartment of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Towako TaguchiDepartment of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Katsuo MoriDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Ayumi YamamuraDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Shotaro NaitoDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Fumiaki AndoDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Shintaro MandaiDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Soichiro IimoriDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Koichiro SusaDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Takayasu MoriDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Kenichi OhashiDepartment of Human Pathology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Eisei SoharaDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Shinichi UchidaDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunoglobulin A nephropathy (IgAN) is a common glomerular renal disease presenting with mesangial cell proliferation and mesangial matrix hyperplasia and is typically treated with oral glucocorticoids. However, the clinical presentations and treatment strategies for certain cases of oral glucocorticoid-resistant IgA nephropathy have not been established. We herein report a case of recurrent IgA nephropathy presenting with nephrotic syndrome and membranoproliferative glomerulonephritis-pattern lesions. A 42-year-old woman presented to our clinic 22 years ago after urinary occult blood was detected during a health examination, leading to a diagnosis of IgA nephropathy based on a renal biopsy. Although temporary remission was achieved with oral glucocorticoid therapy, the relapse occurred repeatedly. Eight years ago, she underwent a third renal biopsy, which revealed grade II (C) and Oxford classification M1E0S1T0 findings. Temporary remission was achieved following tonsillectomy and steroid pulse therapy. Subsequently, she presented with nephrotic syndrome and rapidly increasing urinary protein levels. A fourth renal biopsy revealed membranoproliferative glomerulonephritis (MPGN) pattern lesions that were not previously observed. The administration of cyclosporine and corticosteroids after steroid pulse therapy led to complete remission. In cases of recurrent IgA nephropathy complicated by nephrotic syndrome, MPGN-pattern lesions may underlie this condition. In these cases, both corticosteroids and additional cyclosporine may be effective.

Indexed as

Adrenal Cortex HormonesCyclosporineGlomerulonephritis, IGAGlomerulonephritis, MembranoproliferativeImmunosuppressive AgentsNephrotic SyndromeAdministration, OralAdultDrug Therapy, CombinationFemaleGlucocorticoidsHumansRemission InductionTreatment OutcomeAdrenal Cortex HormonesCyclosporineGlucocorticoidsImmunosuppressive AgentscyclosporineIgA nephropathymembranoproliferative glomerulonephritisnephrotic syndrome

Identifiers

PMID40634092
PMCPMC13019022

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.